IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection

Journal of Cystic Fibrosis

Volumn 15, Issue 6, 2016, Pages 759-768

  Bayes, Hannah K ^a   Ritchie, Neil D ^b   Ward, Christopher ^b   Corris, Paul A ^b,c   Brodlie, Malcolm ^b,d   Evans, Thomas J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

^d Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

Chronic infection; Cystic fibrosis; Interleukin 22; Mucosal immunity; Pseudomonas aeruginosa

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NEUTROPHIL; NONHUMAN; PSEUDOMONAS INFECTION; WEIGHT REDUCTION; WILD TYPE; ANIMAL; CHRONIC DISEASE; DISEASE MODEL; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MUCUS; PATHOPHYSIOLOGY; PNEUMONIA; PROTECTION; PSEUDOMONAS AERUGINOSA;

ANIMALS; CHRONIC DISEASE; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; INTERLEUKINS; LUNG; MICE; MUCUS; PNEUMONIA; PROTECTIVE FACTORS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84998631634     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.06.008     Document Type: Article

References (38)

1. [1] Smith, D.J., Ramsay, K.A., Yerkovich, S.T., Reid, D.W., Wainwright, C.E., Grimwood, K., et al. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres. Respirology 21:2 (Dec 28 2015), 329–337.
2. [2] Folkesson, A., Jelsbak, L., Yang, L., Johansen, H.K., Ciofu, O., Høiby, N., et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol, 10(12), Dec 1 2012, Nature Publishing Group, 841–851.
3. [3] Kerem, E., Viviani, L., Zolin, A., MacNeill, S., Hatziagorou, E., Ellemunter, H., et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J, 43(1), Dec 31 2013, European Respiratory Society, 125–133.
4. [4] Johansen, H.K., Gøtzsche, P.C., Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev, 2015.
5. [5] McAleer, J.P., Kolls, J.K., Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev, 260(1), Jun 19 2014, NIH Public Access, 129–144.
6. [6] Dudakov, J.A., Hanash, A.M., van den Brink, M.R.M., Interleukin-22: immunobiology and pathology. Annu Rev Immunol 33 (2015), 747–785.
7. [7] Sonnenberg, G.F., Nair, M.G., Kirn, T.J., Zaph, C., Fouser, L.A., Artis, D., Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 207:6 (Jun 7 2010), 1293–1305.
8. [8] Aujla, S.J., Chan, Y.R., Zheng, M., Fei, M., Askew, D.J., Pociask, D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14:3 (Mar 1 2008), 275–281.
9. [9] Van Maele, L., Carnoy, C., Cayet, D., Ivanov, S., Porte, R., Deruy, E., et al. Activation of type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection. J Infect Dis 210:3 (Jul 7 2014), 493–503.
10. [10] Peng, Y., Gao, X., Interleukin-22 promotes T helper 1 (Th1)/Th17 immunity in chlamydial lung infection. Mol Med, 20(1), 2014, 1.
11. [11] Ivanov, S., Renneson, J., Fontaine, J., et al. Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection. J Virol, 87(12), Jun 1 2013, American Society for Microbiology (ASM), 6911.
12. [12] Pociask, D.A., Scheller, E.V., Mandalapu, S., et al. IL-22 is essential for lung epithelial repair following influenza infection. Am J Pathol, 182 (4), Apr 1 2013, American Society for Investigative Pathology, 1286–1296.
13. [13] Gessner, M.A., Werner, J.L., Lilly, L.M., Nelson, M.P., Metz, A.E., Dunaway, C.W., et al. Dectin-1-dependent interleukin-22 contributes to early innate lung defense against Aspergillus fumigatus. Infect Immun 80:1 (Dec 22 2011), 410–417.
14. [14] Mear, J.B., Gosset, P., Kipnis, E., et al. Candida albicans airway exposure primes the lung innate immune response against Pseudomonas aeruginosa infection through innate lymphoid cell recruitment and interleukin-22-associated mucosal response. Infect Immun, 82(1), Jan 1 2014, American Society for Microbiology (ASM), 306.
15. [15] Dubin, P.J., Kolls, J.K., IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 292:2 (Feb 1 2007), L519–L528.
16. [16] Bayes, H.K., Bicknell, S., MacGregor, G., Evans, T.J., T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS One, 9(2), 2014, e90263.
17. [17] Chan, Y.R., Chen, K., Duncan, S.R., Lathrop, K.L., Latoche, J.D., Logar, A.J., et al. Patients with cystic fibrosis have inducible IL-17 + IL-22 + memory cells in lung draining lymph nodes. J Allergy Clin Immunol 131:4 (Apr 2013), 1117–1129.
18. [18] Paats, M.S., Bergen, I.M., Bakker, M., Hoek, R.A.S., Nietzman-Lammering, K.J., Hoogsteden, H.C., et al. Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis. Drug Discov Today Dis Model 12:6 (Dec 2013), 623–629.
19. [19] van Heeckeren, A.M., Schluchter, M.D., Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 36:3 (Jul 1 2002), 291–312.
20. [20] Brodlie, M., McKean, M.C., Johnson, G.E., Anderson, A.E., Hilkens, C.M.U., Fisher, A.J., et al. Raised interleukin-17 is immuno-localised to neutrophils in cystic fibrosis lung disease. Eur Respir J 37:6 (2011), 1378–1385.
21. [21] Cigana, C., Lorè, N.I., Riva, C., De Fino, I., Spagnuolo, L., Sipione, B., et al. Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections. Sci Rep, 6, 2016, 21465.
22. [22] Bragonzi, A., Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 300:8 (Dec 2010), 584–593.
23. [23] Van den Broeck, W., Derore, A., Simoens, P., Anatomy and nomenclature of murine lymph nodes: descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J Immunol Methods, 312(1), 2006, Elsevier, 12–19.
24. [24] Hoffmann, N., Rasmussen, T.B., Jensen, P., Stub, C., Hentzer, M., Molin, S., et al. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 73:4 (Mar 21 2005), 2504–2514.
25. [25] Zheng, Y., Danilenko, D.M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:7128 (Feb 8 2007), 648–651.
26. [26] Yen, E.H., Quinton, H., Borowitz, D., Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr 162:3 (Mar 2013), 530–531.
27. [27] Ranganathan, S.C., Parsons, F., Gangell, C., Brennan, S., Stick, S.M., Sly, P.D., et al. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 66:5 (May 2011), 408–413.
28. [28] Wang, X., Ota, N., Manzanillo, P., Kates, L., Zavala-Solorio, J., Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature, 2014.
29. [29] Hasnain, S.Z., Borg, D.J., Harcourt, B.E., Tong, H., Sheng, Y.H., Ng, C.P., et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med, 20(12), Dec 1 2014, Nature Publishing Group, 1417–1426.
30. [30] Shih, V.F.-S., Cox, J., Kljavin, N.M., Dengler, H.S., Reichelt, M., Kumar, P., et al. Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota. Proc Natl Acad Sci U S A 111:38 (Sep 22 2014), 13942–13947.
31. [31] Gauguet, S., D'Ortona, S., Ahnger-Pier, K., Duan, B., Surana, N.K., Lu, R., et al. Intestinal microbiota of mice influences resistance to Staphylococcus aureus pneumonia. Infect Immun, 83(10), Oct 1 2015, American Society for Microbiology (ASM), 4003.
32. [32] Scanlan, P.D., Buckling, A., Kong, W., Wild, Y., Lynch, S.V., Harrison, F., Gut dysbiosis in cystic fibrosis. Drug Discov Today Dis Model 11:5 (Sep 2012), 454–455.
33. [33] Bruzzese, E., Callegari, M.L., Raia, V., Viscovo, S., Scotto, R., Ferrari, S., et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with lactobacillus GG: a randomised clinical trial. Bereswill, S., (eds.) PLoS ONE, 9(2), Feb 19 2014, Public Library of Science, e87796.
34. [34] Singh, P.K., Jia, H.P., Wiles, K., Hesselberth, J., Liu, L., Conway, B.-A.D., et al. Production of β-defensins by human airway epithelia. Proc Natl Acad Sci U S A 96 (1999), 14961–14966.
35. [35] Huang, L.C., Redfern, R.L., Narayanan, S., Reins, R.Y., McDermott, A.M., In vitro activity of human beta-defensin 2 against Pseudomonas aeruginosa in the presence of tear fluid. Antimicrob Agents Chemother 51:11 (Nov 2007), 3853–3860.
36. [36] Kao, C.-Y., Chen, Y., Thai, P., Wachi, S., Huang, F., Kim, C., et al. IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK and NF-κB signaling pathways. J Immunol, 173, 2004.
37. [37] Liang, S.C., Tan, X.Y., Luxenberg, D.P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:10 (Sep 21 2006), 2271–2279.
38. [38] Simonian, P.L., Wehrmann, F., Roark, C.L., Born, W.K., O'Brien, R.L., Fontenot, A.P., γδ T cells protect against lung fibrosis via IL-22. J Exp Med, 207(10), 2010, Rockefeller Univ Press, 2239–2253.